InVivo opens new office and labs in Cambridge, Mass.

Wednesday, September 26, 2012 10:47 AM

InVivo Therapeutics Holdings (NVIV), a developer of technologies for the treatment of spinal cord injuries and neurotrauma, has opened the company’s new office, manufacturing and lab space at in Cambridge, Mass. Consolidating all of InVivo’s operations, the 21,000 square foot facility will serve as the new headquarters for the company.

InVivo Therapeutics received $500,000 in early-stage loan financing through the Massachusetts Life Sciences Center’s accelerator program in 2009 when the company had six employees. The company has since raised $35 million in public financing and has grown to over thirty employees. The Life Sciences Center is the agency charged with implementing the state’s 10-year, $1 billion life sciences initiative.

“InVivo is committed to developing and bringing new therapies to help individuals suffering from spinal cord injuries and other neurological conditions to the market as quickly as possible,” said Frank Reynolds, CEO of InVivo. “We will be able to continue rapidly building our team in the new facility, as well as prepare for the upcoming clinical testing of our lead product. The move into our new headquarters is a critical milestone in our growth and we thank everyone who has helped us reach this point, including the Massachusetts Life Sciences Center, our employees, partners and shareholders.”

Susan Windham-Bannister, president and CEO, Massachusetts Life Sciences Center, said, “InVivo Therapeutics was one of our earliest investments, and we are so proud to see the company expanding in both size and scientific impact. We are pleased to welcome InVivo to their new facility, and look forward to future developments as they advance their important research here in Massachusetts.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 17

PPD, Medidata join their technologies for risk-based monitoring, adaptive trial design

ERT acquires eClinical Insights in "strategic combination" to gain cloud-based trial software platform, expertise

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs